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CASE REPORT

Leiomyosarcoma of Prostate
A Case Report and literature review
Abdeljalil Heddat
, Younes Houry, Redouane Rabii
Mohammed VI University of Health Sciences UM6SS, Cheikh Khalifa Hospital, Casablanca, Morocco
ABSTRACT
Prostate leiomyosarcoma is an extremely rare and very aggressive neoplasm that represents less than 0.1% of primary
malignant tumors of the prostate. We present a patient with primary leiomyosarcoma of prostate and examine the cases
reported in the literature to discuss the clinical, diagnostic, and therapeutic aspects of this rare tumor. Median survival was
estimated at 17 months (95% CI 20.7–43.7 months) and the actuarial survival rates at 1, 3, and 5 years were 68%, 34%, and
26%, respectively. The only predictors of long-term survival were negative surgical margins and the absence of metastatic
disease at presentation. A multidisciplinary approach is necessary for the proper management of this terrible entity.
Surgery with or without chemotherapy seems to be the main therapeutic method for operable leimyosarcomas, but in general,
there is no consensus on the best therapeutic approach. Most cases are diagnosed at an advanced stage of the disease. A
global multicenter trial is needed to find therapies that would improve the prognosis.
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INTRODUCTION
Leiomyosarcoma of the prostate is an extremely rare
malignant tumor that represents less than 0.1% of
primary malignant tumors of the prostate [1]. It is the
most common primary sarcoma of the prostate in adults
and comprises 38% to 52% of primary prostate sarcomas
[2]. It has a more aggressive clinical course compared to
prostatic adenocarcinoma [3]. Its diagnosis is generally
made at a late stage, because of the clinical and
radiological non-specificity. It is often bulky beyond the
prostate gland and invading neighboring organs. His
prognosis remains very grim [3].
CASE REPORT
A 39-year-old patient admitted for voiding disorders
evolving for 6 months in a context of the deterioration of
the general state. On clinical examination, the presence of
a hard hypogastric mass, fixed relative to the deep plane.
On the digital rectal examination, the prostate was
enlarged, nodular, integrating with the bladder base.
Pelvic ultrasound showed heterogeneous prostatic
hypertrophy. The PSA level was normal at 0.46 ng.

The thoraco-abdomino-pelvic scan revealed an enlarged
prostate, heterogeneous after injection of contrast
medium, with areas of necrosis, measuring 140/150/100
mm in diameter. There is an infiltration of the
surrounding fat and urethral vessels, with upstream
bilateral uretero-hydronephrosis. The rectum is pushed
back and presacred without a border of separation with
the prostate tumor, with the presence of multiple hepatic
and pulmonary nodules of secondary appearance (Figure
1).
A prostate biopsy was performed, concluded that a
prostatic leiomyosarcoma (Figure 2).
After bladder catheterization for acute retention of urine,
adjuvant chemotherapy based on Taxotere / gemcitabine
was started combined with analgesic radiotherapy in the
pelvis. After three cycles of chemotherapy, the patient
then received radiotherapy (60 Gy in 30 fractions).
The control scanner showed a slight local improvement,
on the other hand, an aggravation of the secondary
lesions (Figure 3). The patient died a month later.
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Figure 3: Abdominopelvic CT scan after chemotherapy showing
partial radiological improvement.

Figure 1: Abdominopelvic CT scan showing the prostate tumor
invading the bladder. (Cross / sagittal section).

Figure 2: anatomopathological examination showing a
partially necrotic fusocellular tumor proliferation with
positive, strong, and diffuse immunostaining of antidesmine AC tumor cells in favor of prostatic
leiomyosarcoma.
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DISCUSSION
Primary prostate leiomyosarcoma (PLSOP) is the most
common sarcoma affecting the prostate, although it is
generally a rare tumor [5]. PLSOPs cause an obstruction
and tend to involve neighboring organs [5]. The etiology
of PLSOP is unknown or poorly understood [5].
Prostate leiomyosarcoma has been reported in children
and adults ranging from 2.5 years to 80 years of age [6].
PLSOP patients tend to have clinical signs that can
clinically mimic the symptoms of benign prostatic
hypertrophy: pollakiuria, poor urine flow, urgency,
hematuria, and acute urine retention.
Leiomyosarcoma can also present as an exophytic
hypogastric mass of the prostate infiltrating the rectum, a
perineal mass, or by metastases to the liver and lungs [7].
Most cases are diagnosed at an advanced stage of the
disease [7].
Digital rectal examination may show an enlarged prostate
that may appear benign or a hard prostate mass that has
spread to the capsule, rectum, pelvic sidewall, perineum,
and seminal vesicle or involving the base of the bladder
[7,8].
Serum PSA can be normal or high and does not allow the
monitoring of leiomyosarcoma of the prostate after
treatment [8].
Abdominopelvic
ultrasound
would
reveal
hydronephrosis; thickening of the bladder wall or
infiltration of the base of the bladder [9]. Transrectal
prostate ultrasound is a useful technique to better assess
the characteristics of the prostate. It can show
heterogeneous hypoechogenic lesions in the prostate, an
invasion of the capsule or an extension in the rectum, the
pelvic sidewall, the seminal vesicle, or the ejaculatory
duct
[9,10].
Echo-guided transrectal biopsy tends to be the usual
approach to obtain samples of the prostate lesion for the
histological examination which would establish the
diagnosis of leiomyosarcoma of the prostate [7, 9, 10].
Transurethral resection of the prostate for symptoms of
the lower urinary tract or retention of urine may lead to
the accidental diagnosis of leiomyosarcoma during the
histological examination of the resection coupons [1].
Thoracoabdomino-pelvic computed tomography or
magnetic resonance imaging (MRI) can be used to assess
2
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the characteristics of the prostate lesion, its location, and
its local extent. They can indicate whether or not there is
lymphadenopathy or metastases in the abdomen or the
thorax, and also allow the patient to be evaluated and
followed up after treatment. Bone scintigraphy makes it
possible to search for bone metastases [1].
Therapeutic management has not yet been codified and
there is no consensus on the best approach. Several
protocols have been described in the literature [10,11],
radical prostatectomy alone or with chemotherapy or
radiotherapy;
Chemotherapy
and
radiotherapy;
Chemotherapy alone [10]; Radiotherapy alone [11].
Therapeutic combinations include surgery, pre- or postoperative radiotherapy, and neoadjuvant or adjuvant
chemotherapy [12].
Radical retro-pubic prostatectomy is a good curative
option
for
prostatic
sarcoma
[2].
Among the different chemotherapy regimens, an
anthracycline-based combination (doxorubicin or
epirubicin) with alkylating agents (cyclophosphamide,
ifosfamide) and vinca alkaloids (vinblastine or
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with mixed results. [2,10,11]
The 5-year survival of prostatic leiomyosarcoma is very
poor,
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from
0%
to
60%.
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activity
on
biopsy.
[13]
CONCLUSION
Adult prostatic leiomyosarcoma is a rare tumor, often
metastatic when diagnosed, with a normal PSA level. CT
and especially MRI play an important role in the
assessment of extension and post-therapeutic monitoring,
but only the anatomopathological examination,
supplemented by an immunohistochemical study can
confirm the diagnosis. Their therapeutic management is
not codified at present and their prognosis remains very
grim and can only be improved with a multidisciplinary
approach and an early diagnosis, allowing to carry out a
complete radical surgery, the only effective therapy.
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